The company lifted adjusted guidance to $7.30-$7.50 a share, up 30 cents, after first-quarter profit and revenue beat analyst expectations and Aetna delivered stronger-than-expected results.
The new range is above Wall Street estimates, extending a run of upbeat earnings updates from major US health conglomerates.
The increase suggests improving performance at CVS's insurance business is helping support the broader group's outlook for the year.
With new regulations targeting its PBM, can CVS Health's Aetna unit alone sustain its impressive growth trajectory?
As Aetna exits ACA markets and partners with Google, is CVS building a more exclusive or accessible healthcare system?